questionsmedicales.fr
Maladies de l'appareil digestif
Tumeurs de l'appareil digestif
Tumeurs des voies biliaires
Tumeurs des voies biliaires : Questions médicales fréquentes
Termes MeSH sélectionnés :
Multicenter Studies as Topic
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs des voies biliaires : Questions médicales les plus fréquentes",
"headline": "Tumeurs des voies biliaires : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Tumeurs des voies biliaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-20",
"dateModified": "2025-04-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Tumeurs des voies biliaires"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs de l'appareil digestif",
"url": "https://questionsmedicales.fr/mesh/D004067",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs de l'appareil digestif",
"code": {
"@type": "MedicalCode",
"code": "D004067",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C06.301"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs des canaux biliaires",
"alternateName": "Bile Duct Neoplasms",
"url": "https://questionsmedicales.fr/mesh/D001650",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs des canaux biliaires",
"code": {
"@type": "MedicalCode",
"code": "D001650",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C06.301.120.250"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs du cholédoque",
"alternateName": "Common Bile Duct Neoplasms",
"url": "https://questionsmedicales.fr/mesh/D003138",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs du cholédoque",
"code": {
"@type": "MedicalCode",
"code": "D003138",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C06.301.120.250.250"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Tumeurs de la vésicule biliaire",
"alternateName": "Gallbladder Neoplasms",
"url": "https://questionsmedicales.fr/mesh/D005706",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs de la vésicule biliaire",
"code": {
"@type": "MedicalCode",
"code": "D005706",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C06.301.120.401"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs des voies biliaires",
"alternateName": "Biliary Tract Neoplasms",
"code": {
"@type": "MedicalCode",
"code": "D001661",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yasuni Nakanuma",
"url": "https://questionsmedicales.fr/author/Yasuni%20Nakanuma",
"affiliation": {
"@type": "Organization",
"name": "Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan; Department of Diagnostic Pathology, Fukui Prefecture Saiseikai Hospital, Japan. Electronic address: nakanumayasu@gmail.com."
}
},
{
"@type": "Person",
"name": "Takashi Sugino",
"url": "https://questionsmedicales.fr/author/Takashi%20Sugino",
"affiliation": {
"@type": "Organization",
"name": "Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan."
}
},
{
"@type": "Person",
"name": "Yasunori Sato",
"url": "https://questionsmedicales.fr/author/Yasunori%20Sato",
"affiliation": {
"@type": "Organization",
"name": "Department of Human Pathology, Kanazawa University School of Medicine, Kanazawa, Japan."
}
},
{
"@type": "Person",
"name": "Hans-Olov Adami",
"url": "https://questionsmedicales.fr/author/Hans-Olov%20Adami",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden."
}
},
{
"@type": "Person",
"name": "Gary E Fraser",
"url": "https://questionsmedicales.fr/author/Gary%20E%20Fraser",
"affiliation": {
"@type": "Organization",
"name": "School of Public Health, Loma Linda University, Loma Linda, California."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Relationship between critical care nutrition and post-intensive care syndrome in surviving ventilated patients with COVID-19: a multicenter prospective observational study.",
"datePublished": "2023-08-11",
"url": "https://questionsmedicales.fr/article/38292118",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3164/jcbn.23-66"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of liver cirrhosis and portal hypertension on minimally invasive limited liver resection for primary liver malignancies in the posterosuperior segments: An international multicenter study.",
"datePublished": "2023-08-06",
"url": "https://questionsmedicales.fr/article/37591027",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejso.2023.106997"
}
},
{
"@type": "ScholarlyArticle",
"name": "Setting 6-Minute Minimal Examination Time Improves the Detection of Focal Upper Gastrointestinal Tract Lesions During Endoscopy: A Multicenter Prospective Study.",
"datePublished": "2023-08-01",
"url": "https://questionsmedicales.fr/article/37307142",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.14309/ctg.0000000000000612"
}
},
{
"@type": "ScholarlyArticle",
"name": "A multicenter real-world study comparing the clinical equivalence of trastuzumab biosimilar HLX02 and reference trastuzumab in the treatment of HER-2-positive breast cancer.",
"datePublished": "2023-07-15",
"url": "https://questionsmedicales.fr/article/37559995",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
},
{
"@type": "ScholarlyArticle",
"name": "Cefepime vs carbapenems for treating third-generation cephalosporin-resistant AmpC β-lactamase-hyperproducing Enterobacterales bloodstream infections: a multicenter retrospective study.",
"datePublished": "2023-07-14",
"url": "https://questionsmedicales.fr/article/37453486",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ijid.2023.07.004"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de l'appareil digestif",
"item": "https://questionsmedicales.fr/mesh/D004066"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs de l'appareil digestif",
"item": "https://questionsmedicales.fr/mesh/D004067"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs des voies biliaires",
"item": "https://questionsmedicales.fr/mesh/D001661"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Tumeurs des voies biliaires - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Tumeurs des voies biliaires",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Tumeurs des voies biliaires",
"description": "Comment diagnostique-t-on une tumeur des voies biliaires ?\nQuels tests sanguins sont utiles pour le diagnostic ?\nQuelle est l'importance de l'IRM dans le diagnostic ?\nPeut-on utiliser la cholangiographie pour le diagnostic ?\nQuels symptômes peuvent alerter sur une tumeur ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Multicenter+Studies+as+Topic&page=997#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Tumeurs des voies biliaires",
"description": "Quels sont les symptômes courants des tumeurs biliaires ?\nLa jaunisse est-elle un symptôme fréquent ?\nPeut-on avoir des démangeaisons avec une tumeur biliaire ?\nLes nausées sont-elles un symptôme associé ?\nComment la douleur abdominale se manifeste-t-elle ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Multicenter+Studies+as+Topic&page=997#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Tumeurs des voies biliaires",
"description": "Peut-on prévenir les tumeurs des voies biliaires ?\nQuels facteurs de risque sont évitables ?\nL'alimentation joue-t-elle un rôle ?\nLes infections chroniques augmentent-elles le risque ?\nLe tabagisme est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Multicenter+Studies+as+Topic&page=997#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Tumeurs des voies biliaires",
"description": "Quels sont les traitements possibles pour ces tumeurs ?\nLa chirurgie est-elle toujours possible ?\nQuand la chimiothérapie est-elle recommandée ?\nLa radiothérapie est-elle efficace ?\nY a-t-il des traitements ciblés disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Multicenter+Studies+as+Topic&page=997#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Tumeurs des voies biliaires",
"description": "Quelles complications peuvent survenir ?\nL'obstruction biliaire est-elle grave ?\nLes infections sont-elles fréquentes ?\nQuelles sont les conséquences des métastases ?\nPeut-on prévenir les complications ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Multicenter+Studies+as+Topic&page=997#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Tumeurs des voies biliaires",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de tumeurs biliaires ?\nLes maladies hépatiques augmentent-elles le risque ?\nL'exposition à l'arsenic est-elle un risque ?\nLes antécédents familiaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Multicenter+Studies+as+Topic&page=997#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on une tumeur des voies biliaires ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par imagerie (échographie, IRM) et biopsie."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utiles pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent les marqueurs tumoraux comme l'ACE et les tests de fonction hépatique."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de l'IRM dans le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM permet de visualiser les tumeurs et d'évaluer leur extension."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser la cholangiographie pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la cholangiographie permet de visualiser les voies biliaires et détecter des obstructions."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent alerter sur une tumeur ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs abdominales, jaunisse, et démangeaisons peuvent indiquer une tumeur."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des tumeurs biliaires ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur abdominale, jaunisse, et perte de poids."
}
},
{
"@type": "Question",
"name": "La jaunisse est-elle un symptôme fréquent ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la jaunisse est fréquente et résulte d'une obstruction des voies biliaires."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des démangeaisons avec une tumeur biliaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les démangeaisons peuvent survenir en raison de l'accumulation de bile."
}
},
{
"@type": "Question",
"name": "Les nausées sont-elles un symptôme associé ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les nausées peuvent être présentes en raison de l'irritation du système digestif."
}
},
{
"@type": "Question",
"name": "Comment la douleur abdominale se manifeste-t-elle ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "La douleur est souvent localisée dans la partie supérieure droite de l'abdomen."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les tumeurs des voies biliaires ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais éviter l'hépatite et l'alcool peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont évitables ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'alcoolisme et l'exposition à des produits chimiques sont des facteurs évitables."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine peut réduire le risque de maladies hépatiques, mais pas spécifiquement."
}
},
{
"@type": "Question",
"name": "Les infections chroniques augmentent-elles le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections chroniques comme l'hépatite B et C augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est associé à un risque accru de plusieurs cancers, y compris biliaires."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements possibles pour ces tumeurs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la chimiothérapie et la radiothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours possible ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la chirurgie dépend de la taille et de l'emplacement de la tumeur."
}
},
{
"@type": "Question",
"name": "Quand la chimiothérapie est-elle recommandée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie est souvent utilisée pour les tumeurs avancées ou inopérables."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La radiothérapie peut soulager les symptômes et est utilisée en complément."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblés disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements ciblés peuvent être utilisés selon le type de tumeur."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'obstruction biliaire, l'infection et la métastase."
}
},
{
"@type": "Question",
"name": "L'obstruction biliaire est-elle grave ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des douleurs sévères et des infections hépatiques."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections peuvent survenir en raison de l'obstruction des voies biliaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences des métastases ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les métastases peuvent affecter d'autres organes et compliquer le traitement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par un suivi médical régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, l'hépatite chronique et l'exposition à des toxines."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de tumeurs biliaires ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout après 50 ans."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies hépatiques chroniques comme la cirrhose augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'exposition à l'arsenic est-elle un risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à l'arsenic est associée à un risque accru de cancers biliaires."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancers peuvent augmenter le risque."
}
}
]
}
]
}
The impact of nutrition therapy in the acute phase on post-intensive care syndrome (PICS) remains unclear. We conducted a multicenter prospective study on adult patients with COVID-19 who required mec...
To assess the impact of cirrhosis and portal hypertension (PHT) on technical difficulty and outcomes of minimally invasive liver resection (MILR) in the posterosuperior segments....
This is a post-hoc analysis of patients with primary malignancy who underwent laparoscopic and robotic wedge resection and segmentectomy in the posterosuperior segments between 2004 and 2019 in 60 cen...
Of the 1954 patients studied, 1290 (66%) had cirrhosis. Among the cirrhotic patients, 310 (24%) had PHT. After PSM, patients with cirrhosis had higher intraoperative blood transfusion (14% vs. 9.3%; p...
MILR in the posterosuperior segments in cirrhotic patients is associated with higher intraoperative blood transfusion and postoperative morbidity. This parameter should be utilized in the difficulty a...
Positive correlation between examination time and neoplasm detection using esophagogastroduodenoscopy (EGD) has been described by observational studies, but the effect of setting minimal examination t...
This prospective, 2-stage, interventional study was conducted in 7 tertiary hospitals in China, enrolling consecutive patients undergoing intravenously sedated diagnostic EGDs. In stage I, the baselin...
A total of 847 and 1,079 EGDs performed by 21 endoscopists were included in stages I and II, respectively. In stage II, the minimal examination time was set as 6 minutes, and the median time for norma...
Setting a 6-minute minimal examination time significantly improved the detection of focal lesions during EGDs and has the potential to be implemented for quality improvement....
As the first trastuzumab biosimilar introduced in China, there are few studies on the clinical application of HLX02, especially in combination with other antitumour drugs, for the treatment of HER-2-p...
AmpC β-lactamase-hyperproducing Enterobacterales (ABLHE) bloodstream infections (BSI) are emerging and leading to therapeutic challenges worldwide. Prescriptions of carbapenems may lead to the emergen...
This retrospective multicenter study included patients with ABLHE BSI from two tertiary hospitals in France, between July 2017 and July 2022. Non-AmpC-producing Enterobacterales, extended-spectrum β-l...
We analyzed 164 BSI, which included 77 in the cefepime group and 87 in the carbapenem group. In the weighted cohort, the 30-day mortality rates were similar between the cefepime group (23.3%) and the ...
This study adds evidence in favor of the use of cefepime for treating third-generation cephalosporin-resistant ABLHE BSI in case of minimal inhibitory concentration ≤ 1 mg/l, which could spare carbape...
The Phase 3 single-arm COMMODORE 3 study (ClinicalTrials.gov, NCT04654468) evaluated efficacy and safety of crovalimab (novel C5 inhibitor) in complement inhibitor-naive patients with paroxysmal noctu...
In colon cancer, the incidence of postoperative ileus is reportedly higher for the right-side than for the left-side colon, but those studies included small numbers of subjects and contained several b...
This multicenter study reviewed 1986 patients who underwent laparoscopic colectomy between 2016 and 2021 for right-side (n = 907) and left-side (n = 1079) colon cancer. After propensity score matching...
Postoperative ileus occurred in 97 patients. Before matching, the proportion of female patients and median age were higher and frequency of preoperative stent insertion was lower with right colectomy ...
This study revealed a higher risk of postoperative ileus after right colectomy with laparoscopic surgery. Male gender and history of abdominal surgery were risk factors for postoperative ileus after r...
To evaluate the diagnostic performance of the one-step nucleic acid amplification (OSNA) method for the detection of sentinel lymph node (SLN) metastases in women with apparent early-stage endometrial...
Prospective, multicentric, interventional study. Patients with apparent early-stage endometrial cancer who underwent primary surgical staging with SLN mapping were included. SLNs were serially section...
Three-hundred and sixteen patients with 668 SLNs were included. OSNA assay detected 22 (3.3%) positive SLNs, of which 17 (2.5%) were micrometastases and 5 (0.7%) macrometastases, whereas ultrastaging ...
The OSNA method had high specificity and high accuracy in detecting SLN metastasis in apparent early-stage endometrial cancer. The advantage of the OSNA method could be represented as the possibility ...
Evaluation of mismatch repair (MMR) protein and microsatellite instability (MSI) status plays a pivotal role in the management of gastric cancer (GC) patients. In this study, we aimed to evaluate the ...
Acute disorders of consciousness (DoC) in pediatric severe sepsis are associated with increased risk of morbidity and mortality. We sought to examine the frequency of and factors associated with DoC i...
Secondary analysis of the multicenter Phenotyping Sepsis-Induced Multiple Organ Failure Study (PHENOMS)....
Nine tertiary care PICUs in the United States....
Children less than 18 years old admitted to a PICU with severe sepsis and at least one organ failure during a PICU stay....
None....
The primary outcome was frequency of DoC, defined as Glasgow Coma Scale (GCS) less than 12 in the absence of sedatives during an ICU stay, among children with severe sepsis and the following: single o...
One of every five children with severe sepsis and organ failure experienced acute DoC during their PICU stay. Preliminary findings suggest the need for prospective evaluation of DoC in children with s...